{"id":9188,"date":"2025-11-12T12:52:21","date_gmt":"2025-11-12T09:52:21","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9188"},"modified":"2025-11-12T12:52:21","modified_gmt":"2025-11-12T09:52:21","slug":"zalunfiban-at-first-medical-contact-for-stemi-celebrate-trial","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/zalunfiban-at-first-medical-contact-for-stemi-celebrate-trial\/","title":{"rendered":"Zalunfiban at First Medical Contact for STEMI \u2014 CELEBRATE Trial\u00a0"},"content":{"rendered":"
Zalunfiban at First Medical Contact for STEMI \u2014 CELEBRATE Trial<\/div>\n
<\/div>\n
Source: NEJM Evidence, Nov 10 2025<\/div>\n
<\/div>\n
Keynotes:<\/div>\n
1- Background<\/div>\n
\u2022 Zalunfiban (RUC-4) is a new subcutaneous GPIIb\/IIIa inhibitor designed for rapid platelet blockade at first medical contact (FMC) in ST-elevation myocardial infarction (STEMI).<\/span><\/div>\n
\u2022 Aim: To determine if early parenteral platelet inhibition improves infarct-artery patency and short-term outcomes without excess bleeding.<\/span><\/div>\n
<\/div>\n
2-Study Design<\/div>\n
\u2022 Phase 3, international, randomized, double-blind, placebo-controlled trial.<\/span><\/div>\n
\u2022 2,467 STEMI patients enrolled across 8 countries (2021 \u2013 2025).<\/span><\/div>\n
\u2022 Randomized 1:1:1 to:<\/span><\/div>\n
\u2022 Zalunfiban 0.11 mg\/kg (n = 853)<\/span><\/div>\n
\u2022 Zalunfiban 0.13 mg\/kg (n = 818)<\/span><\/div>\n
\u2022 Placebo (n = 796)<\/span><\/div>\n
\u2022 Drug administered at FMC \u2014 home, ambulance, or ED.<\/span><\/div>\n
\u2022 Most patients also received aspirin + heparin \u00b1 ticagrelor.<\/span><\/div>\n
\u2022 Primary efficacy endpoint: 30-day hierarchical composite (death, stroke, recurrent MI, stent thrombosis, HF, large MI, or no event).<\/span><\/div>\n
\u2022 Primary safety endpoint: Severe\/life-threatening bleeding (GUSTO criteria).<\/span><\/div>\n
<\/div>\n
3- Main Results<\/div>\n
\u2022 Efficacy:<\/span><\/div>\n
\u2022 Adjusted OR = 0.79 (95 % CI) vs placebo \u2192 significant clinical benefit.\u00a0 \u00a0 \u00a0 \u00a0OR (Odds Ratio \u2013 a statistical measure indicating the strength of association between a risk factor and an outcome; values >1 suggest higher odds(higher probability)and <1 suggest lower odds).<\/span><\/div>\n
\u2022 \u201cNo event\u201d rate: 13.3 % vs 9.8 %, absolute risk reduction 3.5 %; \u2248 29 patients needed to treat.<\/span><\/div>\n
\u2022 Faster TIMI flow<\/span><\/div>\n
\u2022 Lower stent-thrombosis (0.2 % vs 1.0 %) and fewer large MIs or new-onset HF.<\/span><\/div>\n
\u2022 Safety:<\/span><\/div>\n
\u2022 Severe\/life-threatening bleeding: 1.2 % vs 0.8 % (p = 0.40) \u2192 no significant difference(p < 0.001 \u2013 indicates a highly statistically significant result, meaning the finding is very unlikely due to chance \u2014 less than 0.1% probability, while a result with p > 0.05 is generally considered not statistically significant)<\/span><\/div>\n
\u2022 Mild\u2013moderate bleeding: 6.4 % vs 2.5 % (p < 0.001).<\/span><\/div>\n
\u2022 Thrombocytopenia (<150k\/\u03bcL): 8.1 % vs 6.3 %, mostly grade 1.<\/span><\/div>\n
\u2022 Intracranial hemorrhage: 0.4 % vs 0.6 %.<\/span><\/div>\n
<\/div>\n
4- Interpretation<\/div>\n
\u2022 A single subcutaneous dose at FMC improved early infarct-artery patency and 30-day composite outcomes, without higher major-bleeding risk.<\/span><\/div>\n
\u2022 Represents a potential paradigm shift: converting GPIIb\/IIIa infusion into a field-ready injection usable before PCI.<\/span><\/div>\n
\u2022 Mild bleeding increase warrants monitoring.<\/span><\/div>\n
<\/div>\n
5- Expert Commentary<\/div>\n
\u2022.\u00a0 \u00a0Arnoud van \u2019t Hof \u2013 Maastricht University (Netherlands) et al.: \u201cThese data highlight the efficacy and safety of early subcutaneous platelet inhibition as an adjunct to reperfusion therapy in STEMI.\u201d<\/span><\/div>\n
\u2022 Editorial (d\u2019Entremont & Jolly): CELEBRATE \u201crevives upstream GPIIb\/IIIa therapy\u201d by offering an easy-to-use, rapidly reversible option; further outcome trials are needed before changing guidelines.<\/span><\/div>\n
<\/div>\n
6- Clinical Implications<\/div>\n
\u2022 Upstream parenteral platelet inhibition may enhance pre-PCI reperfusion beyond oral P2Y\u2081\u2082 agents.<\/span><\/div>\n
\u2022 Current guidelines (AHA 2025 \/ ESC 2023) still recommend early oral DAPT; zalunfiban is investigational pending larger mortality-focused trials.<\/span><\/div>\n
<\/div>\n
https:\/\/evidence.nejm.org\/doi\/full\/10.1056\/EVIDoa2500268\ufffc<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Zalunfiban at First Medical Contact for STEMI \u2014 CELEBRATE Trial Source: NEJM Evidence, Nov 10 2025 Keynotes: 1- Background \u2022 Zalunfiban (RUC-4) is a new subcutaneous GPIIb\/IIIa inhibitor designed for rapid platelet blockade at first medical contact (FMC) in ST-elevation myocardial infarction (STEMI). \u2022 Aim: To determine if early parenteral platelet inhibition improves infarct-artery patency […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9188","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9188"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9188\/revisions"}],"predecessor-version":[{"id":9189,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9188\/revisions\/9189"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}